BIIB Biogen Inc.
-
Biogen Beat Consensus Estimates
Wednesday, July 29, 2026 · 12:00 AM ET
Biogen (BIIB) reported earnings of $3.60 per share on revenue of $2.74 billion for the second quarter ended June 2026. The consensus earnings estimate was $3.04 per share on revenue of $2.43 billion. The company beat consensus estimates by 18.42% while revenue grew 3.42% on a year-over-year basis.
Biogen Idec Inc, is a biopharmaceutical company. The Company discovers,
develops, manufactures and markets therapies for neurological, autoimmune and hematologic disorders.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
$3.60
Earnings Whisper®
—
Consensus Estimate
$3.04
Earnings Surprise
Earnings Growth
Reported Revenue
$2.74B
Revenue Estimate
$2.43B
Revenue Surprise
Revenue Growth